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Chemical crop protection is widely used to control plant diseases. However, the adverse
effects of pesticide use on human health and environment, resistance development
and the impact of regulatory requirements on the crop protection market urges
the agrochemical industry to explore innovative and alternative approaches. In that
context, we demonstrate here the potential of camelid single domain antibodies (VHHs)
generated against fungal glucosylceramides (fGlcCer), important pathogenicity factors.
To this end, llamas were immunized with purified fGlcCer and a mixture of mycelium
and spores of the fungus Botrytis cinerea, one of the most important plant pathogenic
fungi. The llama immune repertoire was subsequently cloned in a phage display vector
to generate a library with a diversity of at least 108 different clones. This library was
incubated with fGlcCer to identify phages that bind to fGlcCer, and VHHs that specifically
bound fGlcCer but not mammalian or plant-derived GlcCer were selected. They were
shown to inhibit the growth of B. cinerea in vitro, with VHH 41D01 having the highest
antifungal activity. Moreover, VHH 41D01 could reduce disease symptoms induced
by B. cinerea when sprayed on tomato leaves. Based on all these data, anti-fGlcCer
VHHs show the potential to be used as an alternative approach to combat fungal plant
diseases.
Keywords: camelid antibodies, VHH, antifungal activity, fungal glucosylceramide, Botrytis cinerea, crop
protection
INTRODUCTION
Application of fungicides has been indispensable in modern agriculture to control fungal
diseases and ensure sufficient crop yields. However, such chemical crop protection products face
many challenges including the emergence of resistant pathogens and the search for new active
compounds that combine high activity with favorable toxicology profiles. Therefore, research is
increasingly focusing on innovative and flexible solutions to provide more efficient crop protection.
In nature, plants defend themselves against fungal pathogens by a combination of strategies
including the production of antimicrobial peptides and proteins. An important and evolutionary
conserved family of such antimicrobial peptides are the plant defensins (Terras et al., 1995).
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They are small, cationic peptides with a length of approximately
45–54 amino acids. Their structure typically comprises a
cysteine-stabilized αβ-motif (CSαβ) with a α-helix and a
triple-stranded antiparallel β-sheet that is stabilized by four
disulfide bridges. Their activity is primarily directed against
fungi, but bactericidal and insecticidal actions have also been
reported (De Coninck et al., 2013). The mode of action of
various antifungal plant defensins has been extensively studied
during the last decades and several of their fungal targets
have been identified to date (Vriens et al., 2014). Different
plant defensins specifically interact with different classes of
sphingolipids in the fungal membrane, either inositolphosphoryl-
containing sphingolipids or glucosylceramides (GlcCer). With
respect to the latter, plant defensins of radish (RsAFP2;
Thevissen et al., 2004), pea (Psd1; de Medeiros et al., 2010;
Gonçalves et al., 2012) and alfalfa (MsDef1; Ramamoorthy
et al., 2007) as well as an insect defensin of tobacco budworm
(heliomicin; Thevissen et al., 2004) specifically interact with
fungal GlcCer (fGlcCer). GlcCer are ubiquitous eukaryotic
membrane components that have structural as well as signaling
functions in eukaryotes (Thevissen et al., 2007). Apart from
GlcCer-interacting defensins, there are indications that also
antibodies directed toward fGlcCer possess antifungal activity
(Nimrichter et al., 2004). Hence, it seems that various proteins
or peptides that interact with fGlcCer can inhibit fungal
growth to some extent. This makes fGlcCer an attractive target
for development of novel antifungal compounds for several
reasons (Thevissen et al., 2005; Nimrichter and Rodrigues,
2011; Del Poeta et al., 2014). First, the structure of fGlcCer
is highly conserved in a broad spectrum of fungi while
fGlcCer are structurally different from their mammalian or plant
counterparts (Thevissen et al., 2007; Nimrichter and Rodrigues,
2011). This host-specificity ensures non-toxicity of compounds
that target fGlcCer while maintaining a broad spectrum of
antifungal activity. Second, fGlcCer are important virulence
factors of pathogenic yeasts and fungi (Noble et al., 2010).
Therefore, it can be expected that in vivo resistance development
against the GlcCer-targeting compounds is unlikely to occur.
Indeed, an altered GlcCer composition of the target pathogen
will result in resistance against the GlcCer-targeting compounds,
but concomitantly also in reduced pathogenicity of the mutant
pathogen.
The general aim of this study was to generate novel
compounds that interact with fGlcCer and are characterized by
antifungal activity. To this end, we relied on the antigen-binding
domain of camelid heavy chain antibodies. Camelid species
have, in addition to conventional IgG antibodies, heavy chain
antibodies that are composed of homodimers of two heavy
chains only (Hamers-Casterman et al., 1993). Conventional
IgG antibodies consist of three major fragments: two identical
antigen-binding fragments and an Fc part (Padlan, 1994).
The antigen-binding fragment in conventional antibodies (Fab)
consists of a light chain of two domains (VL-CL) and two
of four domains of the heavy chain (VH-CH1). Functional
antigen binding of heavy chain antibodies is achieved by a
single domain that is called VHH, a small 15 kDa protein
with excellent stability and particularly high affinity and
specificity for the targets to which they are raised. VHHs can
be easily cloned as they are encoded by single genes, have
high antigen affinity and selectivity, possess good solubility
and can be efficiently produced in micro-organisms such as
Escherichia coli, Saccharomyces cerevisiae, or Pichia pastoris
(Arbabi Ghahroudi et al., 1997; Frenken et al., 2000; van de Laar
et al., 2007).
Hence, in this study, we engineered fGlcCer-targeting VHHs
and assessed their GlcCer-interacting capacity and antifungal
activity in vitro and in vivo against plant pathogenic fungi.
MATERIALS AND METHODS
Materials
Purified (99%) glucosylceramide (GlcCer) from Pleurotus
citrinopileatus (Tamigotake) was purchased form Nacalai
Tesque (Japan). Soybean and porcine GlcCer were purchased
from Avanti Polar Lipids (Alabama, United States). Fusarium
oxysporum GlcCer was obtained from Professor Eliana Barreto
Bergter of the Universidade Federal do Rio de Janeiro (Brazil).
For immunization, GlcCer from P. citrinopileatus was dissolved
in a methanol:chloroform:water mixture (16:16:5, v/v/v) and
spotted on a TLC (Thin Layer Chromatography) silica glass plate
(Sigma–Aldrich). Silica with adsorbed GlcCer was scraped from
the plate and suspended in phosphate buffer (1 mg/ml). The
other GlcCer samples were dissolved in a chloroform:methanol
mixture (2:1, v/v).
For immunization, a mixture was prepared from 1E+07
Botrytis cinerea (B05.10) spores (see below) and 3.5 mg
homogenized B. cinerea mycelium. For the latter, B. cinerea
mycelium was grown in culture flasks containing half strength
PDB (12 g/l Potato Dextrose Broth medium (Lab M, United
Kingdom)) for 3 days at room temperature. The mycelium was
recovered using a filter covered with Miracloth and resuspended
in phosphate buffer.
Botrytis cinerea (R16, B05.10, kindly provided by Rudi
Aerts, KU Leuven, Belgium), Verticillium dahliae (MUCL19210),
F. culmorum (MUCL30162), F. graminearum (MUCL30161)
and Alternaria brassicicola (MUCL20297) were used to test the
antifungal activity of VHHs. Cultivation and spore harvesting
was performed as described previously (Broekaert et al., 1990).
Spores were collected from V. dahliae and B. cinerea grown
on half strength PDB (12 g/l Potato Dextrose Broth medium
(LABM, United Kingdom), 15 g/l select agar) and A. brassicicola,
F. culmorum, and F. graminearum on 6CA-medium (cereal agar;
20 g/l baby cereals (Nestlé), 15 g/l select agar).
Recombinant Raphanus sativus AFP2 (RsAFP2) was produced
in P. pastoris and purified from the supernatant as previously
described (Vriens et al., 2016).
Tomato (Solanum lycopersicum) cv. Castlemart was grown
at 22◦C in a greenhouse with 75% relative humidity in a 16-h
light/8-h dark regime.
Animal Immunizations
Two llamas were subcutaneously immunized twice with 100 µg
GlcCer and four times with 50 µg GlcCer together with
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FIGURE 1 | Schematic overview of library construction and screening of VHHs with fGlcCer binding and antifungal activity.
incomplete Freund’s adjuvant (Sigma–Aldrich) following
a two-weekly time schedule. Subsequently these llamas
were also boosted three times with a mixture of 1E+07
B. cinerea spores and 3.5 mg mycelium following a two-weekly
time schedule. All llamas remained healthy throughout
the immunization process and blood samples were taken
7 days after the last GlcCer immunizations and B. cinerea
boost, respectively. All vaccination experiments are executed
according to EU animal welfare legislation and after approval
of the local ethics (CNREEA : C2EA – 14). All animals are
registered, manipulated by authorized staff, and an experienced
veterinarian.
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Library Construction
Figure 1 gives a schematic overview of the library construction.
Peripheral blood mononuclear cells were prepared from 0.4 L
blood of the immunized llamas using Ficoll-Hypaque according
to the manufacturer’s instructions (GE Healthcare). Total RNA
was extracted from these cells using the RNeasy Maxi Kit
(Qiagen) and used as starting material for cDNA synthesis using
the Superscript III First-strand cDNA kit (Invitrogen). First
strand cDNA synthesis is followed by RT-PCR using the forward
primers Lib1 (5′-GGCTGAGCTGGGTGGTCCTGG-3′) and
Lib2 (5′-GGCTGAGTTTGGTGGTCCTGG-3′) and the reverse
primer Lib3 (5′-GGTACGTGCTGTTGAACTGTTCC-3′)
(de Haard et al., 2014). The VHH encoding gene
fragments are excised from agarose gel and amplified
by PCR using the following specific primers: Lib5
(5′-AAATGAGGAGACGGTGACCTGGGT) and Lib7 (5′-
CATTTGAGTTGGCCTAGCCGGCCATGGCACAGGTGCAG
CTGCAGGAGTCTGGGGG-3′). The gel-purified PCR-
products were digested with SfiI and Eco91I and ligated
into the phagemid vector pASF20. pASF20 is an expression
vector that is derived from pUC119 which contains the lacZ
promotor, a synthetic leader sequence, a multiple cloning
site, a coliphage pIII protein coding sequence, a resistance
gene for ampicillin, and an M13 phage origin for single
strand production. In frame with the VHH coding sequence,
the vector codes for a C-terminal (His)6 peptide tag and
c-myc peptide tag. The ligation products were transformed
into TG1 E. coli competent cells. Four libraries each with
a clonal diversity equal to or greater than 1E+08 were
obtained.
VHH Selection by Phage Display
Phages were prepared according to standard methods described
in Kay et al. (1996) and phage display selection was performed
according to Verheesen and Laeremans (2012).
Fungal glucosylceramides from P. citrinopileatus and
F. oxysporum were used as targets to isolate the phage expressing
fGlcCer-binding VHHs. fGlcCer from P. citrinopileatus,
dissolved in methanol:chloroform:water mixture (16:16:5,
v/v/v) and the fGlcCer from F. oxysporum dissolved in
chloroform:methanol (2:1, v/v) were diluted in methanol
and immobilized on polystyrene Nunc Maxisorp R© 96-well
plates by overnight evaporation at room temperature. Wells
with coated fGlcCer (10 µg for P. citrinopileatus GlcCer
and 1 µg for F. oxysporum GlcCer in 100 µl) were washed
three times with phosphate buffer and blocked with 1% fish
gelatin (Sigma–Aldrich). Aliquots (100 µl) of the blocked
phage premix were added to the wells and incubated for 2 h
at room temperature on a shaking platform. The wells were
washed 15 times with phosphate buffer and bound phages were
eluted with trypsin (0.1 mg/ml). Two consecutive rounds of
selections were performed, one campaign using P. citrinopileatus
GlcCer in the first round and F. oxysporum GlcCer in the
second round and one campaign using F. oxysporum GlcCer
in both rounds. Individual clones were picked from second
round selections for further characterization by sequence
analysis (LGC group) and primary binding assays. Periplasmic
extracts were prepared from 96-well plate produced cultures.
Nunc Maxisorp R© plates were coated with 1 µg F. oxysporum
GlcCer as described above. The plates were blocked with 1%
fish gelatin and 10-fold diluted VHH-containing periplasmic
extracts were incubated for 1 h at room temperature in
1% BSA/1% Gelatin. After the plates were washed they were
incubated with mouse anti-histidine antibodies and anti-mouse
alkaline phosphatase antibodies (Sigma–Aldrich). Finally, the
enzyme activity was determined with the alkaline phosphatase
substrate (Sigma–Aldrich). The optical density was measured at
405 nm.
VHH Purification
For further characterization, VHHs were produced in E. coli
in culture flasks according to standard procedures (Marks
et al., 1991). His-tagged VHHs were purified from the
periplasmic extracts using the ÄKTAxpress using a combination
of immobilized Nickel IMAC and desalting columns, according
to the manufacturer’s instructions (GE Healthcare Life Sciences).
Characterization of Anti-GlcCer VHH
Using ELISA
Nunc Maxisorp R© plates were coated with 1 µg F. oxysporum,
10 or 1 µg P. citrinopileatus and 1 µg soybean or porcine
GlcCer as described above. The plates were blocked with 1%
fish gelatin and purified VHHs (1 µg/ml) were incubated
for 1 h at room temperature in 1% BSA/1% Gelatin. After
the plates were washed they were incubated with mouse
anti-histidine antibodies and anti-mouse alkaline phosphatase
antibodies (Sigma–Aldrich). Finally, the enzyme activity
was determined with the alkaline phosphatase substrate
(Sigma–Aldrich). The optical density was measured at
405 nm.
TABLE 1 | Overview of immunizations, libraries and master plate selections.
Immunization Boost Library sets Selection Master plates
GlcCer from P. citrinopileatus B. cinerea spores and
mycelium
Four libraries (2 after
P. citrinopileatus and 2 after P.
citrinopileatus + B. cinerea
boost)
1st round with GlcCer from
P. citrinopileatus
MP39 – MP40
1st round with GlcCer from
P. citrinopileatus and 2nd round
with GlcCer from F. oxysporum
MP41 – MP42
MP50 – MP53
Two rounds with GlcCer from
F. oxysporum
MP54 – MP57
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FIGURE 2 | Interaction of VHHs with fGlcCer. Optical density values (absorbance at 405 nm) represent the interaction of 10-fold diluted crude VHH-containing
periplasmic extracts to 10 µg coated GlcCer from Pleurotus citrinopileatus. VHH A and B are unrelated VHHs; the blank control represents a value for the ELISA
experiment without VHH present.
Antifungal Activity
The antifungal activity of the VHHs against a range of plant
pathogenic fungi was analyzed following the protocol previously
described (Osborn et al., 1995) with some modifications. Briefly, a
twofold dilution series of the VHHs in sterile water was prepared
in 96-well plates, after which 10 µl of VHH was mixed with
90 µl of half strength PDB containing 5E+04 spores/ml of the
fungus. 96-well plates were incubated at 21◦C in the dark for 48 or
72 h after which the mycelium growth was visually determined as
compared to the control (i.e., water) treatment, using an inverted
microscope (Motic AE21).
Disease Assay
Detached leaves of 6-week old tomato plants were sprayed
using an airbrush (VidaXL, nozzle diameter of 0.35 mm) until
runoff with 60 µM VHH 41D01 resuspended in 0.2 × PBS
(phosphate buffered saline) Tween20 (0.01%) or with a mock
solution [0.2 × PBS Tween20 (0.01%)]. After 24 h, 10 leaves
of five different plants were each inoculated with four 5-µl
droplets of 1E+05 spores/ml of B. cinerea B05.10 and stored
in plastic chambers on wet paper at high humidity (>99%).
Lesion diameters were measured 3, 4, and 5 days post inoculation.
Data were statistically analyzed with Two-way ANOVA and
Bonferroni post-test. The experiment was repeated three times
with similar results.
RESULTS
Generation and Selection of
fGlcCer-Targeting VHHs
The aim of this study was to generate VHHs against fGlcCer and
to select those VHHs that exhibit binding to fGlcCer. Figure 1
provides a schematic overview of the library construction. To
select for fGlcCer-binding VHHs via phage display, two llamas
were immunized with six boosts of commercially available
fGlcCer from the fungus P. citrinopileatus and three additional
boosts of a mixture of homogenized mycelium and spores of
the fungus B. cinerea. All llamas remained healthy throughout
the immunization process. Four phage libraries each with a
clonal diversity higher than 1E+08 were obtained and used in
the selection procedure (Table 1). For this, fGlcCer from P.
citrinopileatus or F. oxysporum were coated and incubated with
phages. Non-binding and fast-dissociating phages were washed
away and specific phages remained bound to the fGlcCer. After
two rounds of selections a total of 12 master plates containing
1128 individual clones were selected for further analysis by
sequencing and primary binding assays (Table 1). Primary
binding assays were performed via an ELISA-based binding assay
with VHH-containing periplasmic extracts and GlcCer from
P. citrinopileatus. Interestingly, 130 VHH-containing periplasmic
extracts showed to bind fGlcCer with higher OD 405 nm values
than the unrelated VHH A and VHH B or blank controls
(Supplementary Figure S1), indicating that the enrichment was
successful. Sequence analysis revealed 79 unique sequences from
the identified set of anti-GlcCer VHH. To select the strongest
binding and most specific fGlcCer interactors for further study
we also took into account the binding ratio - i.e., the ratio of
the absorbance of the interaction experiment with and without
fGlcCer. Clones with the highest ratio were selected. Figure 2
represents the 20 most potent VHHs with a binding ratio higher
than 4.
To further characterize the selected VHHs, a specificity ELISA
was performed. For this, the selected VHHs were produced
in E. coli and purified from the periplasmic extracts. Typical
yields were 0.5–10 mg purified VHH per liter culture. VHHs
54D03 and 53F05 were not obtained in sufficient quantities and
therefore not pursued further. To test binding specificity of the
purified VHHs, 1 µg/ml VHH was incubated with coated GlcCer
from P. citrinopileatus, F. oxysporum, Glycine max (soybean) and
porcine. Although the binding capacity of the VHHs toward
the fGlcCer varied strongly (Figure 3A), none of the VHHs
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FIGURE 3 | Specific Interaction of VHHs with fGlCer and antimicrobial activity of selected VHHs. (A) Optical density values (absorbance at 405 nm, depicted in left
Y-axis) represent the interaction of 1 µg/ml purified VHH to coated GlcCer from Fusarium oxysporum or Pleurotus citrinopileatus and was evaluated in an
ELISA-based binding assay. VHH B is an unrelated VHH. The antimicrobial activity of 12 VHHs was tested against Botrytis cinerea. Growth of B. cinerea R16
mycelium was microscopically determined 48 h after addition of different concentrations of VHHs. Minimal inhibitory concentrations at which at least 95% of the
growth of the fungus was inhibited (IC95), compared to the control without added VHH, are indicated with a red dot and represent an average of two biological
replicates. IC95 values are depicted in the right Y-axis. (B) Percentage growth of B. cinerea 48 h post co-incubation with different concentrations of VHH 41D01
(gray line) or the plant defensin RsAFP2 (black line). Data points represent the mean ± SE of three biological replicates.
showed binding capacity toward plant or mammalian GlcCer
(Supplementary Figure S2).
fGlcCer-Binding VHHs Display In Vitro
Antifungal Activity
Twelve VHHs were selected for further characterization and
tested in vitro for antifungal activity against B. cinerea. The
minimal inhibitory concentration at which 95% of the fungal
growth was inhibited (IC95) varied between 47 and 198 µg/ml
(between 3 and 13 µM) (Figure 3A) with VHH 41D01 having
the highest activity, and approximately as potent as the plant
defensin RsAFP2 (Figure 3B). To test whether VHH 41D01 has
broad antifungal activity we determined its inhibitory activity
against the fungal plant pathogens F. culmorum, F. graminearum,
V. dahliae, and A. brassicicola. VHH 41D01 also inhibited the
growth of these fungi (IC95 < 12 µM) (Figure 4) showing it
has broad spectrum activity. RsAFP2 was taken along as positive
control.
VHH 41D01 Reduces Disease Symptoms
of B. cinerea When Sprayed on Tomato
Leaves
To further test the in vivo efficacy of VHH 41D01, we
evaluated disease symptom development of detached
tomato leaves inoculated with B. cinerea (B05.10) 24 h
after spraying the leaves with 60 µM VHH 41D01 or a
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FIGURE 4 | Antifungal activity of VHH 41D01. Graphs represent percentage growth of the different fungi Verticillium dahliae (96h post incubation, hpi), F. culmorum
(72hpi), Alternaria brassicicola (72hpi) and F. graminearum (96hpi) post co-incubation with different concentrations of RsAFP2 (black lines) and VHH 41D01 (gray
lines). Data points represent the mean ± SE of three biological replicates.
mock solution [0.2 × PBS Tween20 (0.01%)]. Compared
to the control treatment, VHH 41D01 reduced disease
symptoms induced by B. cinerea by approximately 50%
(Figure 5).
DISCUSSION
Here we show that anti-fGlcCer VHHs have potential to
combat fungal plant diseases. Previously, several reports
focusing on human fungal pathogens showed that fGlcCer is
a potential target for the development of novel antifungals
(Thevissen et al., 2005; Nimrichter and Rodrigues, 2011; Del
Poeta et al., 2014). First, GlcCer are ubiquitous eukaryotic
membrane components, yet those found in fungal cells are
structurally different from those in human cells. Indeed,
we confirmed that anti-fGlcCer VHHs specifically bind
fGlcCer without cross-reactivity for mammalian or plant
GlcCer (Supplementary Figure S2). Secondly, fGlcCer are
important for fungal development including cell division,
hyphal formation, alkaline tolerance and spore germination
(Nimrichter and Rodrigues, 2011; Del Poeta et al., 2014).
In addition, fGlcCer appear to play a central role in signal
transduction and cell regulation (Hannun and Luberto,
2000; Thevissen et al., 2006). Thirdly, GlcCer of human
fungal pathogens are correlated with fungal pathogenicity
(Luberto et al., 2001; Rittershaus et al., 2006; Noble et al.,
2010; Nimrichter and Rodrigues, 2011). For example, a
1gcs1 strain of Cryptococcus neoformans, lacking the GlcCer
synthase (GCS), loses its pathogenicity. Also for fungal
plant pathogens GlcCer seem to play a role in pathogenicity
although this effect seems to depend on the host. While a
1gcs1 strain from the fungal plant pathogen F. graminearum
is less virulent on wheat spikelets it retains full virulence on
tomato fruits and Arabidopsis thaliana floral and foliar tissues
(Ramamoorthy et al., 2007). In accordance, a 1gcs1 strain of
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FIGURE 5 | In vivo antifungal activity of VHH 41D01. Tomato leaves were sprayed with VHH 41D01 or a control solution [0.2 × PBS Tween20 (0.01%)]. After a
drying period of 24 h, leaves were inoculated with 5 µl drops of 1E+05 spores/ml of B. cinerea. (A) Bars represent average lesion diameter (mm) scored at 3, 4, and
5 days post inoculation (dpi), error bars represent standard errors of the mean with n = 10. Significant differences between control treatment (gray bars) and VHH
41D01 treatment (white bars) are marked with an asterisk (∗p < 0.05, ∗∗∗p < 0.001). (B) Picture of tomato leaves treated with VHH 41D01 showing no infection after
artificial inoculation compared to leaves treated with mock solutions.
Penicillium digitatum showed reduced symptom development
on citrus fruits compared to the wild-type strain (Zhu et al.,
2014).
Antifungal compounds that either directly target fGlcCer
or its biosynthesis and, hence, affect fungal development
and infection, can be expected to combat efficiently fungal
infections. Indeed, several antimicrobial plant defensins and
the insect defensin heliomicin, have been reported to interact
specifically with fGlcCer or require fGlcCer to exert their
antifungal activity (Thevissen et al., 2004; Ramamoorthy et al.,
2007; de Medeiros et al., 2010). More specifically for plant
pathogenic fungi, it has been reported that the 1gcs1 strain of
F. graminearum is resistant to defensins from, e.g., Medicago
sativa (MsDef1) and radish (RsAFP2) (Ramamoorthy et al.,
2007). Moreover, transgenic expression of both plant defensins
in various crop plants rendered the plants less susceptible
to fungal pathogens (De Coninck et al., 2013). In line,
anti-GlcCer antibodies that specifically interact with fGlcCer
seem to inhibit fungal growth in vitro and also in vivo
since it has been demonstrated that passive immunization
with a monoclonal antibody to GlcCer significantly reduces
host inflammation and prolongs the survival of mice lethally
infected with C. neoformans (Rodrigues et al., 2000, 2007;
Nimrichter et al., 2004). Also inhibitors of fGlcCer were reported
to be highly effective in vitro and in vivo against fungal
human pathogens (Mor et al., 2015). Recently, it was shown
that administration of fGlcCer in a mouse model of fungal
infection is a good vaccination strategy as it can protect mice
against lethal doses of infection by C. neoformans (Mor et al.,
2016).
Corroborating all the above data obtained in animal
model systems that suggest antifungal activity for antibodies
directed against fGlcCer, we show in this study that
treatment of plants with anti-fGlcCer VHHs can reduce
infection by phytopathogenic fungi such as the broad-
spectrum pathogen B. cinerea ranked as second most
important fungal plant pathogen based on scientific/economic
importance (Dean et al., 2012). A comparable reduction
of disease symptoms has also been reported in oat treated
with defensins of Nicotiana alata and subsequently
inoculated with Puccinia coronata (Dracatos et al.,
2014).
For the development of a spray-on biological crop protection
product it is most important that anti-fGlcCer VHHs are
non-toxic, can be cost-effectively produced on industrial scale,
can be stably formulated, and can exert their antifungal
activity after being sprayed on the crop of interest and
exposed to dry conditions for a certain period of time.
The favorable safety profile of VHHs is a consequence
of both their specificity and proteinaceous nature. Anti-
fGlcCer VHHs are derived from naturally occurring antibodies
and we showed that they bind with high specificity to
fGlcCer. Compared to full-length monoclonal antibodies,
VHHs have several advantages including their reduced size
(approximately 120 amino acids), high solubility facilitating
their high level recombinant production, their stability at
high temperatures or mild concentrations of detergent, and
their capacity to functionally refold after thermal, chemical or
pressure denaturation (van der Linden et al., 1999; Dumoulin
et al., 2002; Dolk et al., 2005). And yet, environmentally
VHHs are supposedly easily degradable proteins compared
to chemical compounds residing long in the environment.
High-level secretion of VHHs by different yeasts such as
S. cerevisiae, and P. pastoris has been described (Gorlani et al.,
2012; De Meyer et al., 2014). VHH’s potentials has led to
their development as therapeutics, in diagnostics, in affinity
chromatography, as co-crystallizing chaperones, in preventing
protein aggregation, for tuning enzyme functions, and more
(de Marco et al., 2011; De Meyer et al., 2014; Wang et al.,
2016). Altogether, we expect that VHHs have the same potential
as biological crop protection product and after completing the
challenges in production and formulation constitute a novel class
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of biological crop protection products. VHHs can be generated
against virtually any target and VHHs may be developed as
biological fungicides, insecticides, and potentially more.
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FIGURE S1 | Interaction of VHHs with fGlcCer. Optical density values (absorbance
at 405 nm) represent the interaction of 10-fold diluted crude VHH-containing
periplasmic extracts to 10 µg coated GlcCer from Pleurotus citrinopileatus.
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at 405 nm) represent the interaction of 1 µg/ml purified VHH to coated GlcCer
from porcine or soybean and was evaluated in an ELISA-based binding assay.
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